Evaxion AS (EVAX)
6.45
+0.08
(+1.26%)
USD |
NASDAQ |
Dec 11, 16:00
6.32
-0.13
(-2.02%)
After-Hours: 07:40
Evaxion Research and Development Expense (Quarterly): 2.158M for March 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Novo Nordisk A/S | 2.410B |
| Ascendis Pharma A/S | 76.00M |
| DBV Technologies SA | 26.82M |
| Cellectis SA | 19.34M |
| Akari Therapeutics Plc | 0.2475M |